Biotech & Health Tech
STAT+: PepGen says early trial for muscular dystrophy drug looks promising
PepGen says its candidate is correcting more of the genetic stutter found in myotonic dystrophy type 1.
PepGen says its candidate is correcting more of the genetic stutter found in myotonic dystrophy type 1.
This is a summary of the story. Read the full article at Stat News (Biotech & Health Tech) ↗